Metformin Inhibits Angiogenesis Induced by Interaction of Hepatocellular Carcinoma with Hepatic Stellate Cells

Cell Biochemistry and Biophysics

Volumn 71, Issue 2, 2015, Pages 931-936

  Qu, Hongmei ^a   Yang, Xingwang ^b  

^a WEIFANG PEOPLE'S HOSPITAL   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Hepatic stellate cells; Hepatocellular carcinoma; Metformin; Tumor microenvironment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN;

DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); STELLATE CELL; TUMOR MICROENVIRONMENT; UMBILICAL VEIN ENDOTHELIAL CELL;

AMP-ACTIVATED PROTEIN KINASES; ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; HEP G2 CELLS; HEPATIC STELLATE CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; METFORMIN; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84925485439     PISSN: 10859195     EISSN: 15590283     Source Type: Journal    
DOI: 10.1007/s12013-014-0287-8     Document Type: Article

References (29)

1. World Health Organization. Mortality database. Available at http://www.who.int/whosis/whostat/EN_WHS08_Part1.pdf. Accessed 4 Dec 2008.
2. Bosetti, C., Levi, F., Boffetta, P., et al. (2008). Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology,48, 137–145.
3. El-Serag, H. B., Tran, T., & Everhart, J. E. (2004). Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology,126, 460–468.
4. El-Serag, H. B., Richardson, P. A., & Everhart, J. E. (2001). The role of diabetes in hepatocellular carcinoma: a case–control study among United States veterans. American Journal of Gastroenterology,96, 2462–2467.
5. Verlato, G., Bonora, E., Zoppini, G., & Muggeo, M. (2003). Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care,26, 1047–1051.
6. Inoue, M., Iwasaki, M., Otani, T., et al. (2006). Diabetes mellitus and the risk of cancer: Results from a large-scale population based cohort study in Japan. Archives of Internal Medicine,166, 1871–1877.
7. Lai, M. S., Hsieh, M. S., Chiu, Y. H., & Chen, T. H. H. (2006). Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology,43, 1295–1302.
8. Chen, C. L., Yang, H. I., Yang, W. S., et al. (2008). Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: A follow-up study in Taiwan. Gastroenterology,135, 111–121.
9. Donadon, V., Balbi, M., Casarin, P., Vario, A., & Alberti, A. (2008). Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: Potential role of insulin. World Journal of Gastroenterology,14(37), 5695–5700.
10. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ,330, 1304–1305.
11. Hanahan, D., & Coussens, L. M. (2012). Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell,21, 309–322.
12. Hernandez-Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013). Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology,144, 512–527.
13. Dapito, D. H., Mencin, A., Gwak, G. Y., Pradere, J. P., Jang, M. K., Mederacke, I., et al. (2012). Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell,21, 504–516.
14. Friedman, S. L. (2008). Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiological Reviews,88, 125–172.
15. Coulouarn, C., Corlu, A., Glaise, D., Guénon, I., Thorgeirsson, S. S., & Clément, B. (2012). Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Research,72, 2533–2542.
16. Kang, N., Gores, G. J., & Shah, V. H. (2011). Hepatic stellate cells: Partners in crime for liver metastases? Hepatology,54, 707–713.
17. Santamato, A., Fransvea, E., Dituri, F., Caligiuri, A., Quaranta, M., Niimi, T., et al. (2011). Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clinical Science,121, 159–168.
18. Yang, Z. F., & Poon, R. T. (2008). Vascular changes in hepatocellular carcinoma. The Anatomical Record,291, 721–734.
19. Lin, N., Chen, Z., Lu, Y., Li, Y., Hu, K., & Xu, R. (2014). Role of activated hepatic stellate cells in proliferation and metastasis of hepatocellular carcinoma. Hepatology Research,. doi:10.1111/hepr.12356.
20. Eiró, N., & Vizoso, F. J. (2014). Importance of tumor/stroma interactions in prognosis of hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition,3(2), 98–101.
21. Sandhu, D. S., Baichoo, E., & Roberts, L. R. (2014). Fibroblast growth factor signaling in liver carcinogenesis. Hepatology,59(3), 1166–1173.
22. Zhang, Z. L., Zhang, J. F., Yuan, Y. F., He, Y. M., Liu, Q. Y., Mao, X. W., et al. (2014). Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody. Experimental and Therapeutic Medicine,7(3), 543–552. Epub 2014 Jan 7.
23. Zhao, W., Zhang, L., Xu, Y., Zhang, Z., Ren, G., Tang, K., et al. (2014). Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Laboratory Investigation,94(2), 182–191.
24. Hardie, D. G. (2004). The AMP-activated protein kinase pathway–new players upstream and downstream. Journal of Cell Science,117, 5479–5487.
25. Luo, Z., Saha, A. K., Xiang, X., & Ruderman, N. B. (2005). AMPK, the metabolic syndrome and cancer. Trends in Pharmacological Sciences,26, 69–76.
26. Shaw, R. J. (2006). Glucose metabolism and cancer. Current Opinion in Cell Biology,18, 598–608.
27. Yamaguchi, R., Yano, H., Nakashima, O., Akiba, J., Nishida, N., Kurogi, M., et al. (2006). Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma. Journal of Gastroenterology and Hepatology,21, 152–160.
28. Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998). Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology,28, 68–77.
29. Uematsu, S., Higashi, T., Nouso, K., Kariyama, K., Nakamura, S., Suzuki, M., et al. (2005). Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology,20, 583–588.